Herbert Loong, Advisor at Greater Bay Area International Clinical Trial Institute, and Steering Committee Member at Lung Cancer Policy Network, shared a post on X:
“Antibody Drug Conjugates are emerging as a key platform of treatment delivery in lung cancer.
Happy to share a couple of key slides on this topic presented at ASCOMOS26.”
You can also read:
Could Proton Pump Inhibitors Affect Durvalumab Outcomes After Chemoradiotherapy in Stage III NSCLC?
